EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Interferon Lambda: The Next Frontier in Antiviral Therapy?

Sofia Chronopoulou, Ilias Tsochantaridis iD

Pharmaceuticals · 24.05.2025 · 18 (6) · 785

DOI: 10.3390/ph18060785 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 24.05.2025. Verfasst von Sofia Chronopoulou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type III interferons (IFN-λ) are the most recently identified members of the interferon family, distantly related to type I interferons and members of the interleukin-10 (IL-10). Unlike type I interferons, which have broadly distributed cellular receptors, IFN-λ signals through a heterodimeric receptor complex with primary expression on epithelial cells. This restricted receptor distribution makes IFN-λ a favorable candidate for therapeutic and antiviral applications with reduced side effects. In this review, we describe the molecular structure, signaling mechanisms, and the role of IFN-λ in the innate immunity of epithelial tissue, which are its primary sites of action. Moreover, this review will summarize and critically examine the antiviral potential of IFN-λ based on all published clinical trials conducted for the treatment of COVID-19, and hepatitis B, C and D virus. Furthermore, this review suggests IFN-λ as a promising therapeutic recombinant protein, with special emphasis on its potential for production using alternative expression and advanced drug delivery systems. To emphasize its potential as a therapeutic intervention, the design and engineering of recombinant IFN-λ will be presented, with a focus on its lower side-effect profile compared to Type I interferons.

Schlagwörter

Stichwörter der Autor:innen

COVID-19antiviral therapycytokineshepatitis Bhepatitis Chepatitis Dinterferon lambda

Autor:innen und Institutionen

  • Department of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.

ORCID-Profile: Ilias Tsochantaridis

Zitieren

APA

Chronopoulou, S., & Tsochantaridis, I. (2025). Interferon Lambda: The Next Frontier in Antiviral Therapy?. Pharmaceuticals, 18(6), 785. https://doi.org/10.3390/ph18060785

Vancouver

Chronopoulou S, Tsochantaridis I. Interferon Lambda: The Next Frontier in Antiviral Therapy?. Pharmaceuticals. 2025;18(6):785. doi:10.3390/ph18060785

BibTeX
@article{Chronopoulou2025,
  author = {Chronopoulou, Sofia and Tsochantaridis, Ilias},
  title = {Interferon Lambda: The Next Frontier in Antiviral Therapy?},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {6},
  pages = {785},
  doi = {10.3390/ph18060785}
}
Kostenlos starten →